Efficacy and safety of Canagliflozin (CANA), an inhibitor of Sodium Glucose Co-Transporter 2 (SGLT2), added on to insulin therapy with or without oral agents in type 2 diabetes (T…
D Matthews, G Fulcher, V Perkovic, D de Zeeuw, KW Mahaffey, J Rosenstock, M Davies, G Capuano, M Desai, W Shaw, F Vercruysse, G Meininger, B Neal · Diabetologie und Stoffwechsel · 2013 · Heft 04
Bibliografische Angaben
Zusammenfassung
Question: SGLT2 inhibition is a novel treatment modality for T2D. We report here a pre-specified substudy of the CANagliflozin cardioVascular Assessment Study (CANVAS) defining the efficacy and safety of CANA in subjects with T2D on insulin. Methodology: CANVAS is a double-blind, placebo (PBO)-controlled study that randomized 4,330 individuals at elevated cardiovascular risk to the addition of CANA 100 or 300 mg or PBO once daily to stable ongoing diabetes therapy. The subgroup using insulin (≥30 IU/d) included 565, 566, and 587 subjects, respectively. Primary endpoint for this substudy was change from baseline…
